Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 29;13(7):1077.
doi: 10.3390/jpm13071077.

The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis

Anastasiia Yu Filatova  1 , Olga I Afanasieva  1 , Tatiana I Arefieva  1 , Alexandra V Potekhina  2 , Alexandra V Tyurina  2 , Elena A Klesareva  1 , Oksana A Razova  1 , Marat V Ezhov  2 , Sergey N Pokrovsky  1
Affiliations

The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis

Anastasiia Yu Filatova et al. J Pers Med. .

Abstract

In this study we analyzed the concentration of lipoprotein(a) (Lp(a)), PCSK9-Lp(a) complexes and the circulating monocyte subsets in coronary atherosclerosis. For this study, 257 patients with coronary atherosclerosis and 68 patients without stenotic atherosclerosis in the coronary, carotid and lower extremity arteries (control group) were enrolled. The monocyte subpopulations (classical CD14++CD16-, intermediate CD14++CD16+ and non-classical CD14+CD16++) were analyzed by direct immunofluorescence and flow cytometry. The Lp(a) and PCSK9-Lp(a) complexes in the serum were detected by ELISA. The concentration of Lp(a) was higher in the coronary atherosclerosis group compared with the controls (23.0 (9.1; 73.3) mg/dL versus 10.7 (4.7; 25.0) mg/dL, p < 0.05). No correlations between the level of Lp(a) and the concentration of the PCSK9-Lp(a) complexes, nor between the level of Lp(a) or PCSK9 and the total number of monocytes, were observed in either group. A slight positive correlation between the concentration of PCSK9-Lp(a) complexes and the absolute level of monocytes was obtained (r = 0.20, p = 0.002) in the patients with atherosclerosis due to the intermediate monocyte subsets (r = 0.33, p = 0.04). According to regression analysis, both the PCSK9-Lp(a) complexes concentration and BMI were related to the absolute number of blood monocytes in patients with atherosclerosis. Further studies are required to determine the pathogenetic contribution of PCSK9-Lp(a) complexes to the development of atherosclerosis.

Keywords: PCSK9; PCSK9-Lp(a); atherosclerosis; lipoprotein(a); monocytes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The proportion of patients with a level of Lp(a) ≥ 30 mg/dL in coronary atherosclerosis and controls groups. Data are presented as n (%). Abbreviations: Lp(a) = lipoprotein(a).
Figure 2
Figure 2
Levels of PCSK9-Lp(a) complexes according to monocyte quartiles in patients with atherosclerosis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Afanasieva O.I., Pokrovsky S.N. Hyperlipopproteinemia(a) as a dangerous genetically determined violation of lipid metabolism and a risk factor for atherothrombosis and cardiovascular diseases. Russ. J. Cardiol. 2019;24:101–108. doi: 10.15829/1560-4071-2019-5-101-108. - DOI
    1. Tmoyan N.A., Afanasieva O.I., Ezhov M.V., Klesareva E.A., Balakhonova T.V., Pokrovsky S.N. Lipoprotein(a), immunity, and inflammation in polyvascular atherosclerotic disease. J. Cardiovasc. Dev. Dis. 2021;8:11. doi: 10.3390/jcdd8020011. - DOI - PMC - PubMed
    1. Guedon A.F., De Freminville J.-B., Mirault T., Mohamedi N., Rance B., Fournier N., Paul J.-L., Messas E., Goudot G. Association of lipoprotein(a) levels with incidence of major adverse limb events. JAMA Netw. Open. 2022;5:e2245720. doi: 10.1001/jamanetworkopen.2022.45720. - DOI - PMC - PubMed
    1. Naglic D.T., Manojlovic M., Pejakovic S., Stepanovic K., Simeunovic J.P. Lipoprotein(a): Role in atherosclerosis and new treatment options. Biomol. Biomed. 2023. online ahead of print . - PMC - PubMed
    1. Suwa S., Ogita M., Miyauchi K., Sonoda T., Konishi H., Tsuboi S., Wada H., Naito R., Dohi T., Kasai T., et al. Impact of lipoprotein(a) on long-term outcomes in patients with coronary artery disease treated with statin after a first percutaneous coronary intervention. J. Atheroscler. Thromb. 2017;24:1125–1131. doi: 10.5551/jat.38794. - DOI - PMC - PubMed